Cargando…
Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review
A 48-year-old multiple myeloma patient with renal insufficiency developed sustained bleeding after vein puncture. Coagulation studies showed a prolonged activated partial thromboplastin time and thrombin time. Addition of an equal volume of normal plasma did not correct the activated partial thrombo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797914/ https://www.ncbi.nlm.nih.gov/pubmed/35117336 http://dx.doi.org/10.21037/tcr-20-1968 |
_version_ | 1784641668642766848 |
---|---|
author | Shen, Haorui Wu, Chao Chen, Lijuan Zhang, Run |
author_facet | Shen, Haorui Wu, Chao Chen, Lijuan Zhang, Run |
author_sort | Shen, Haorui |
collection | PubMed |
description | A 48-year-old multiple myeloma patient with renal insufficiency developed sustained bleeding after vein puncture. Coagulation studies showed a prolonged activated partial thromboplastin time and thrombin time. Addition of an equal volume of normal plasma did not correct the activated partial thromboplastin time completely, while the prolonged thrombin time was corrected by protamine sulfate in vitro, which indicated the presence of heparin-like anticoagulants. In our case, both of the infusion of fresh-frozen plasma or dialysis had no significant effect on the coagulation studies or the bleeding time. The patient achieved complete remission after 2 cycles of chemotherapy (bortezomib combined with cyclophosphamide and dexamethasone), meanwhile the bleeding stopped and the abnormal coagulation studies were corrected, which suggest that myeloma cells may be a source of heparin-like anticoagulants. But the source of heparin-like anticoagulants is unclear. It is worth noting that the type of M protein of our patient is IgD lambda light chain and lambda light chain, which is not reported in previous literatures, and the special type of M protein may be the source of heparin-like anticoagulants in our patient. Heparin-like anticoagulants may lead to severe bleeding in multiple myeloma patients, so early evaluation of the coagulation function of multiple myeloma patients is clinically important for early intervention. |
format | Online Article Text |
id | pubmed-8797914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87979142022-02-02 Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review Shen, Haorui Wu, Chao Chen, Lijuan Zhang, Run Transl Cancer Res Case Report A 48-year-old multiple myeloma patient with renal insufficiency developed sustained bleeding after vein puncture. Coagulation studies showed a prolonged activated partial thromboplastin time and thrombin time. Addition of an equal volume of normal plasma did not correct the activated partial thromboplastin time completely, while the prolonged thrombin time was corrected by protamine sulfate in vitro, which indicated the presence of heparin-like anticoagulants. In our case, both of the infusion of fresh-frozen plasma or dialysis had no significant effect on the coagulation studies or the bleeding time. The patient achieved complete remission after 2 cycles of chemotherapy (bortezomib combined with cyclophosphamide and dexamethasone), meanwhile the bleeding stopped and the abnormal coagulation studies were corrected, which suggest that myeloma cells may be a source of heparin-like anticoagulants. But the source of heparin-like anticoagulants is unclear. It is worth noting that the type of M protein of our patient is IgD lambda light chain and lambda light chain, which is not reported in previous literatures, and the special type of M protein may be the source of heparin-like anticoagulants in our patient. Heparin-like anticoagulants may lead to severe bleeding in multiple myeloma patients, so early evaluation of the coagulation function of multiple myeloma patients is clinically important for early intervention. AME Publishing Company 2020-11 /pmc/articles/PMC8797914/ /pubmed/35117336 http://dx.doi.org/10.21037/tcr-20-1968 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Case Report Shen, Haorui Wu, Chao Chen, Lijuan Zhang, Run Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title | Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title_full | Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title_fullStr | Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title_full_unstemmed | Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title_short | Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
title_sort | acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797914/ https://www.ncbi.nlm.nih.gov/pubmed/35117336 http://dx.doi.org/10.21037/tcr-20-1968 |
work_keys_str_mv | AT shenhaorui acquiredheparinlikeanticoagulationprocessinapatientwithmultiplemyelomaacasereportandliteraturereview AT wuchao acquiredheparinlikeanticoagulationprocessinapatientwithmultiplemyelomaacasereportandliteraturereview AT chenlijuan acquiredheparinlikeanticoagulationprocessinapatientwithmultiplemyelomaacasereportandliteraturereview AT zhangrun acquiredheparinlikeanticoagulationprocessinapatientwithmultiplemyelomaacasereportandliteraturereview |